Shares of bioMerieux (OTCMKTS:BMXMF - Get Free Report) dropped 3.5% on Monday . The company traded as low as $137.51 and last traded at $137.51. Approximately 4 shares changed hands during mid-day trading, an increase of 51% from the average daily volume of 3 shares. The stock had previously closed at $142.45.
Wall Street Analyst Weigh In
Separately, Royal Bank Of Canada downgraded bioMerieux from a "moderate buy" rating to a "hold" rating in a research note on Wednesday, May 7th.
Read Our Latest Stock Analysis on bioMerieux
bioMerieux Stock Performance
The company has a debt-to-equity ratio of 0.08, a quick ratio of 1.29 and a current ratio of 2.20. The company has a 50 day moving average of $138.64 and a 200 day moving average of $128.26.
About bioMerieux
(
Get Free Report)
bioMérieux SA develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries.
See Also
Before you consider bioMerieux, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and bioMerieux wasn't on the list.
While bioMerieux currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access